"
Team:Panama
From 2010.igem.org
(Difference between revisions)
| Line 96: | Line 96: | ||
align="justify"><span style="color: rgb(0, 0, 0);"><span | align="justify"><span style="color: rgb(0, 0, 0);"><span | ||
style="font-family: sans-serif;"><span | style="font-family: sans-serif;"><span | ||
| - | style="font-size: 0.4cm;"> | + | style="font-size: 0.4cm;">Rhamnolipids are naturally occurring glycolipids produced by the Pseudomonas aeruginosa. Rhamnolipids have many applications, because of their natural biosurfactant, emulsifying, fungicidal, antibiotic, and pharmaceutical properties. Also rhamnolipids can operate in extreme conditions such as high temperature, pH, and salinity. They have a low toxicity, and they are biodegradable compared to their synthetic chemical counterparts. Rhamnolipid is composed of rhamnose sugar molecule and b-hydroxyalkanoic acid. The rhamnosyltransferase 1 complex (RhlAB) is the key enzyme responsible for transferring the rhamnose moiety to the b-hydroxyalkanoic acid moiety to biosynthesize rhamnolipid. Since the organisms known to produce rhamnolipids are almost exclusively pathogens. For this reason, we propose the non-pathogenic nature of E. coli as an attractive candidate for commercial rhamnolipid production by assembling our rhamnosyltransferase 1 gene (rhlAB) into a BioBrick using synthetic biology to engineer these new rhamnosyltransferase 1 producing bacteria for human benefit.</span></span></span></span></p> |
| - | + | ||
| - | and | + | |
| - | + | ||
| - | + | ||
| - | + | ||
Revision as of 15:15, 13 July 2010
